Display options
Cite
Lohith TG, Osterweil EK, Fujita M, et al. Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. Mol Autism. 2013;4(1):15doi: 10.1186/2040-2392-4-15.
Lohith, T. G., Osterweil, E. K., Fujita, M., Jenko, K. J., Bear, M. F., & Innis, R. B. (2013). Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. Molecular autism, 4(1), 15. https://doi.org/10.1186/2040-2392-4-15
Lohith, Talakad G, et al. "Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?." Molecular autism vol. 4,1 (2013): 15. doi: https://doi.org/10.1186/2040-2392-4-15
Lohith TG, Osterweil EK, Fujita M, Jenko KJ, Bear MF, Innis RB. Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. Mol Autism. 2013 May 24;4(1):15. doi: 10.1186/2040-2392-4-15. PMID: 23706040; PMCID: PMC3679853.
Copy Download .nbib Format: NLM
Share it on

Mol Autism. 2013 May 24;4(1):15. doi: 10.1186/2040-2392-4-15.

Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?.

Molecular autism

Talakad G Lohith, Emily K Osterweil, Masahiro Fujita, Kimberly J Jenko, Mark F Bear, Robert B Innis

Affiliations

  1. Molecular Imaging Branch, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892-1026, USA. [email protected].

PMID: 23706040 PMCID: PMC3679853 DOI: 10.1186/2040-2392-4-15

Abstract

BACKGROUND: Fragile X syndrome (FXS) is a common inherited form of intellectual disability caused by loss of function of the fragile X mental retardation protein. Recent animal studies suggest that upregulated downstream signaling by metabotropic glutamate receptor 5 (mGluR5) might be an important mechanism for cognitive and behavioral abnormalities associated with FXS. However, mGluR5 density in human FXS remains unknown.

METHODS: Receptor binding and protein expression were measured in the postmortem prefrontal cortex of 14 FXS patients or carriers and 17 age- and sex-matched control subjects without neurological disorders. In-vitro binding assays were performed using [3H]-labeled 3-methoxy-5-pyridin-2-ylethynylpyridine (MPEPy), a selective and high-affinity negative allosteric modulator of mGluR5, to measure receptor density and the radioligand's dissociation constant, which is inversely proportional to affinity. Immunoblotting was also performed, to measure mGluR5 protein expression.

RESULTS: The mGluR5 density increased with marginal significance (+16%; P = 0.058) in the prefrontal cortex of FXS patients or carriers compared with matched healthy controls. No significant change in dissociation constant (-4%; P = 0.293) was observed. Immunoblotting found a significant elevation (+32%; P = 0.048) in mGluR5 protein expression.

CONCLUSIONS: Both mGluR5 binding density and protein expression were increased in the brains of FXS patients or carriers, but only expression was significantly different, which could be because of the small sample size and moderate variability. Another important caveat is that the effects of psychotropic medications on mGluR5 expression are largely unknown. Future in-vivo measurement of mGluR5 with positron emission tomography might characterize the role of this receptor in the pathophysiology of FXS and facilitate trials of mGluR5-oriented treatments for this disorder.

References

  1. Neuron. 2007 Dec 20;56(6):955-62 - PubMed
  2. J Nucl Med. 2007 Feb;48(2):247-52 - PubMed
  3. Nucleic Acids Res. 2001 Jun 1;29(11):2276-83 - PubMed
  4. Q J Nucl Med Mol Imaging. 2008 Sep;52(3):245-53 - PubMed
  5. Trends Neurosci. 2004 Jul;27(7):370-7 - PubMed
  6. Sci Transl Med. 2011 Jan 5;3(64):64ra1 - PubMed
  7. J Med Genet. 2009 Apr;46(4):266-71 - PubMed
  8. Cell. 2001 Nov 16;107(4):477-87 - PubMed
  9. Mol Autism. 2010 Sep 21;1(1):12 - PubMed
  10. Neuropharmacology. 2005 Dec;49(7):1053-66 - PubMed
  11. J Nucl Med. 2008 Dec;49(12):2042-8 - PubMed
  12. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7746-50 - PubMed
  13. Neuron. 2007 Aug 16;55(4):565-71 - PubMed
  14. Neuropsychopharmacology. 2012 Jan;37(1):178-95 - PubMed
  15. Curr Protein Pept Sci. 2012 Jun;13(4):358-71 - PubMed
  16. J Neurosci. 2005 Sep 28;25(39):8908-16 - PubMed
  17. J Neurodev Disord. 2011 Sep;3(3):211-24 - PubMed
  18. J Neurol. 2012 Mar;259(3):401-13 - PubMed
  19. EMBO J. 2010 Apr 7;29(7):1248-61 - PubMed
  20. Cell. 1991 Aug 23;66(4):817-22 - PubMed
  21. Methods Mol Biol. 2011;746:135-64 - PubMed
  22. Mol Autism. 2011 May 06;2:6 - PubMed
  23. Pediatrics. 2009 Jan;123(1):378-90 - PubMed

Publication Types